Avoro Capital Advisors LLC Has $147.17 Million Holdings in uniQure N.V. $QURE

Avoro Capital Advisors LLC grew its stake in uniQure N.V. (NASDAQ:QURE) by 38.4% in the fourth quarter, HoldingsChannel reports. The fund owned 6,150,000 shares of the biotechnology company’s stock after acquiring an additional 1,705,556 shares during the period. uniQure accounts for 1.4% of Avoro Capital Advisors LLC’s holdings, making the stock its 19th largest position. Avoro Capital Advisors LLC owned 0.10% of uniQure worth $147,170,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently modified their holdings of the stock. Aberdeen Group plc grew its stake in shares of uniQure by 25.1% during the fourth quarter. Aberdeen Group plc now owns 3,678,640 shares of the biotechnology company’s stock valued at $88,030,000 after purchasing an additional 738,897 shares during the last quarter. State Street Corp boosted its holdings in uniQure by 123.8% in the fourth quarter. State Street Corp now owns 3,231,043 shares of the biotechnology company’s stock valued at $77,319,000 after acquiring an additional 1,787,033 shares during the last quarter. JPMorgan Chase & Co. increased its position in uniQure by 155.3% in the fourth quarter. JPMorgan Chase & Co. now owns 2,934,626 shares of the biotechnology company’s stock worth $70,226,000 after purchasing an additional 1,785,275 shares during the period. Franklin Resources Inc. increased its position in uniQure by 23.9% in the third quarter. Franklin Resources Inc. now owns 1,988,581 shares of the biotechnology company’s stock worth $116,073,000 after purchasing an additional 383,066 shares during the period. Finally, Sofinnova Investments Inc. raised its holdings in uniQure by 185.5% during the 2nd quarter. Sofinnova Investments Inc. now owns 1,558,356 shares of the biotechnology company’s stock worth $21,723,000 after purchasing an additional 1,012,585 shares during the last quarter. 78.83% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have recently issued reports on QURE shares. Wolfe Research began coverage on shares of uniQure in a research note on Monday, February 23rd. They issued a “peer perform” rating on the stock. Mizuho raised shares of uniQure from a “neutral” rating to an “outperform” rating and boosted their price target for the stock from $12.00 to $35.00 in a research note on Wednesday, March 11th. Sanford C. Bernstein lowered shares of uniQure to a “market perform” rating in a report on Tuesday, March 3rd. Wells Fargo & Company raised shares of uniQure from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $15.00 to $60.00 in a research note on Monday, March 9th. Finally, Barclays upgraded shares of uniQure from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $25.00 to $65.00 in a research report on Thursday. Twelve equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, uniQure has a consensus rating of “Moderate Buy” and an average target price of $58.92.

Insider Transactions at uniQure

In other uniQure news, insider Jeannette Potts sold 5,237 shares of the stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $27.67, for a total transaction of $144,907.79. Following the completion of the transaction, the insider owned 133,246 shares in the company, valued at approximately $3,686,916.82. This represents a 3.78% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Kylie O’keefe sold 15,936 shares of uniQure stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $27.06, for a total value of $431,228.16. Following the completion of the sale, the insider directly owned 108,864 shares in the company, valued at $2,945,859.84. This represents a 12.77% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 101,054 shares of company stock worth $2,655,791. Company insiders own 4.65% of the company’s stock.

Trending Headlines about uniQure

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: The FDA’s feedback now appears to support a near-term biologics license application for AMT-130, increasing the odds of accelerated approval for Huntington’s disease and boosting sentiment around uniQure’s lead program. Reuters
• Positive Sentiment: Barclays upgraded uniQure and raised its price target to $65 from $25, reflecting a more constructive view of the company after the FDA development. Benzinga
• Positive Sentiment: uniQure also announced preliminary AMT-260 data in refractory mesial temporal lobe epilepsy, saying the treatment was generally well tolerated with no serious adverse events so far and early signs of biological activity. GlobeNewswire
• Neutral Sentiment: Insider selling by a director and an executive has drawn attention, but the trades were disclosed and at least one was made under a pre-arranged 10b5-1 plan, so they are less likely to be interpreted as a fundamental warning sign.
• Neutral Sentiment: Several articles argue the stock may still be undervalued after the FDA update, but those calls mostly reflect optimism already fueled by the regulatory news rather than a new company-specific catalyst. Yahoo Finance

uniQure Stock Performance

NASDAQ QURE opened at $46.29 on Friday. uniQure N.V. has a one year low of $8.73 and a one year high of $71.50. The company has a debt-to-equity ratio of 0.33, a current ratio of 10.40 and a quick ratio of 10.40. The firm has a market cap of $2.92 billion, a P/E ratio of -13.30 and a beta of 0.98. The stock’s 50-day moving average is $24.74 and its 200-day moving average is $22.20.

uniQure (NASDAQ:QURE) last posted its earnings results on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.03. uniQure had a negative return on equity of 145.81% and a negative net margin of 1,154.42%.The business had revenue of $3.56 million during the quarter, compared to analysts’ expectations of $5.21 million. Sell-side analysts anticipate that uniQure N.V. will post -3.64 earnings per share for the current fiscal year.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.